West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter. Asian Pacific Journal of Cancer Prevention 1513-7368 21 12 2020 12 01 Evaluation of Genetic Polymorphisms of N-acetyltransferase 2 and Relation with Chronic Myeloid Leukemia 3711 3717 89406 10.31557/APJCP.2020.21.12.3711 EN Entesar M Tebien Faculty of Medical Laboratory Sciences, Department oF Hematology, Al Neelain University, Sudan. Faculty of Applied Medical Sciences, Clinical Laboratory Sciences, Shaqra University, Saudi Arabia. Hiba B Khalil Faculty of Medical Laboratory Sciences, Al Neelain Stem Cell Center, Al Neelain University, Sudan. Jeremy Mills School of Pharmacy and Biomedical Sciences, University of Portsmouth, UK. Abozer Y Elderdery Faculty of Applied Medical Sciences, Clinical Laboratory Sciences, Jouf University, Saudi Arabia. Faculty of Medical Laboratory Sciences, Department of Hematology, University of El Imam El Mahdi, Sudan. 0000-0002-6219-5312 Journal Article 2020 05 01 Objectives: The N-Acetyltransferase 2 (NAT2) gene encodes a key enzyme involved in xenobiotic metabolism, which contributes to the detoxification of numerous cancer therapy-induced products. However, the NAT2 genotype/phenotype is not fully understood and few studies have reported its relationship with CML. The aim of this study was to determine whether its polymorphisms (C481T, G590A, 803A>G and 857G>A) have a role in chronic myeloid leukemia susceptibility (CML) in Sudanese population. Methods: We performed a case- control study. DNA from 200 CML patients and 100 controls was analyzed for the NAT2 polymorphisms using PCR-RFLP assay. Results: The study showed NAT2 polymorphisms 803AG are associated with CML protection by a factor of 2.3, (OR = 0.044, 95% CI: 0.020-0.095, p = 0. 000). The study indicated that the heterozygous (GA) and mutant (AA) variants of the G857A genotype also offer protection, (OR = 0.002, 95% CI: 0.002-0.019, p = 0. 000) and (OR = 0.018, 95% CI: 0.002-0.133, p = 0. 000), respectively. Conclusion: There was no significant difference in CML diagnosis among Sudanese cases with the 481C→T and 590G→A polymorphisms. But patients with the compound NAT2 genotypes 481CT/803 AG, 590AG/ 803AG, 590AG/ 803GG, 590AA/ 803AG and 590GG/ 803AG were found to have a reduced risk. The current study demonstrates that polymorphisms of NAT2 A803G and G857A might also act as protective factors against developing the disease. https://journal.waocp.org/article_89406_9ac3209b37b27c95af6c7c3b7ec12b5f.pdf